Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eight-year follow-up study of brain atrophy in patients with MS.
Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA. Fisher E, et al. Neurology. 2002 Nov 12;59(9):1412-20. doi: 10.1212/01.wnl.0000036271.49066.06. Neurology. 2002. PMID: 12427893 Clinical Trial.
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Balcer LJ, et al. Neurology. 2007 Apr 17;68(16):1299-304. doi: 10.1212/01.wnl.0000259521.14704.a8. Neurology. 2007. PMID: 17438220 Clinical Trial.
MRI features of pediatric multiple sclerosis.
Banwell B, Shroff M, Ness JM, Jeffery D, Schwid S, Weinstock-Guttman B; International Pediatric MS Study Group. Banwell B, et al. Neurology. 2007 Apr 17;68(16 Suppl 2):S46-53. doi: 10.1212/01.wnl.0000259406.09052.75. Neurology. 2007. PMID: 17438238
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Rudick RA, et al. Ann Neurol. 2007 Oct;62(4):335-46. doi: 10.1002/ana.21163. Ann Neurol. 2007. PMID: 17696126 Clinical Trial.
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Calabresi PA, et al. Neurology. 2007 Oct 2;69(14):1391-403. doi: 10.1212/01.wnl.0000277457.17420.b5. Epub 2007 Aug 29. Neurology. 2007. PMID: 17761550 Clinical Trial.
Thalamic atrophy and cognition in multiple sclerosis.
Houtchens MK, Benedict RH, Killiany R, Sharma J, Jaisani Z, Singh B, Weinstock-Guttman B, Guttmann CR, Bakshi R. Houtchens MK, et al. Neurology. 2007 Sep 18;69(12):1213-23. doi: 10.1212/01.wnl.0000276992.17011.b5. Neurology. 2007. PMID: 17875909
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Hutchinson M, et al. J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. J Neurol. 2009. PMID: 19308305 Free article. Clinical Trial.
594 results